Why the study?
Adiponectin is protective in cardiovascular disease but limited by short half-life and production cost, prompting study of whether the agonist AdipoRon alleviates fatty acid-induced cardiomyocyte injury.
Does AdipoRon alleviate palmitic acid-induced cardiomyocyte injury?
Does AdipoRon alleviate palmitic acid-induced cardiomyocyte injury?
AdipoRon protects cardiomyocytes from lipotoxicity-induced injury by suppressing Nlrp3 inflammasome activation, suggesting potential therapeutic value for obesity-related cardiac disease.
Answers are grounded in this paper and cite their sources.
AdipoRon may protect cardiomyocytes from lipotoxicity in vitro; leaves open in vivo efficacy and clinical translation in diabetic cardiomyopathy.
BACKGROUND: Hypoadiponectinemia is a high risk factor for type 2 diabetes and cardiovascular disease. Although adiponectin is a protective molecule in cardiovascular diseases, it is hampered due to short plasma half-life and high cost of production. This study aimed to investigate whether AdipoRon, a small-molecule adiponectin receptor agonist, alleviated saturated free fatty acids such as palmitic acid (PA)-induced cardiomyocyte injury by suppressing Nlrp3 inflammasome activation. METHODS: Cell viability was used with MTT assay. Cell apoptosis and mitochondria membrane potential were detected by flow cytometry. We also detected the ROS production and colocolization of inflammasome protein with fluorescence and immunofluorescence microscopic analysis, respectively. Then, IL-1β was detected by Elisa assay and other protein expression was analyzed by Western blot. RESULTS: Our observations demonstrated PA dose-dependently promoted the cell injury, and such high lipotoxicity induced impairment of cardiomyocytes was significantly attenuated by AdipoRon treatment. Moreover, PA markedly activated the first phase of Nlrp3 inflammasome (NF-ƙb) signaling. Notably, the stimulation of PA enhanced ROS production as regulators of Nlrp3 inflammasome activation. In addition, treatment with PA increased the Nlrp3 inflammasome protein expression and complex formation, while AdipoRon abolished it. Lastly, the suppressive effect of AdipoRon to PA-induced cell injury and Nlrp3 inflammasome activation was significantly reversed by Nlrp3 siRNA and pan-caspase inhibitor (z-vad-fmk). CONCLUSION: Taken together, these data suggested that AdipoRon suppressed PA-induced myocardial cell injury by suppressing Nlrp3 inflammasome activation. Thus, AdipoRon might possess potent protective effect in lipotoxicity injury such as obesity leading to cardiac disease.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: